Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
暂无分享,去创建一个
G. Ahmann | R. Fonseca | B. Djulbegovic | A. Cantor | W. Dalton | D. Sullivan | S. Sebti | S. Kaufmann | A. Adjei | J. Wright | P. Greipp | L. Bruzek | T. Price-Troska | M. Alsina | E. Gerbino | Edward Wilson | R. Overton | A. Belle | R. M. Overton | E. Wilson